Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Beximco Pharmaceuticals
Beximco Pharmaceuticals
Activities:
Manufacturing
Drug Delivery
Pharmaceutical
X
LinkedIn
Trending Articles
Optimising RNA production for faster and cheaper pharmaceutical manufacturing
RNA production can be a lengthy and complex process, but the Ntensify platform could change this by diminishing development times, decreasing production costs and allowing the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool
The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Ingredients
Beximco Pharma receives US FDA approval for antiarryhtmic drug Flecainide
Marks the company's eighth product approval for the US market
Ingredients
Beximco Pharma introduces first generic remdesivir for COVID-19
Beximco Pharma is donating remdesivir (Bemsivir) to the Bangladesh Government for supply only to Government hospitals
Personal Protection
Beximco Pharma donates PPE for the COVID-19 fight
Bangladeshi group has contributed $1.8 million to support this initiative
Finance
Mylan chooses Beximco for exclusive antibody distribution in Bangladesh
Beximco Pharma has received the exclusive rights to launch Netherlands-based Mylan’s portfolio of key monoclonal antibodies in its headquarters of Bangladesh
Manufacturing
Beximco Pharma: The Bangladeshi company connecting with the US
COO Rabbur Reza talks about the strategy behind approaching pharmaceutical manufacturing from an emerging market
Regulatory
Beximco receives FDA approval for generic allergy drug
The nod for Bangladesh-based company is for the antihistamine drug, Cyproheptadine Hydrochloride, a generic equivalent of Periactin tablets form Merck
Regulatory
Beximco Pharma gets eight ANDAs from Sandoz
Deal with Novartis' division to boost Beximco's export sales to the US
Subscribe now